Spikevax (previously COVID-19 Vaccine Moderna) Evropska unija - slovenščina - EMA (European Medicines Agency)

spikevax (previously covid-19 vaccine moderna)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cepiva - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Comirnaty Evropska unija - slovenščina - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cepiva - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. uporaba tega cepiva mora biti v skladu z uradnimi priporočili.

NOAX 50 mg orodisperzibilne tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

noax 50 mg orodisperzibilne tablete

angelini pharma Ősterreich gmbh - tramadol - orodisperzibilna tableta - tramadol 43,92 mg / 1 tableta - tramadol

NOAX 50 mg orodisperzibilne tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

noax 50 mg orodisperzibilne tablete

angelini pharma Ősterreich gmbh - tramadol - orodisperzibilna tableta - tramadol 43,92 mg / 1 tableta - tramadol

NOAX 50 mg orodisperzibilne tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

noax 50 mg orodisperzibilne tablete

angelini pharma Ősterreich gmbh - tramadol - orodisperzibilna tableta - tramadol 43,92 mg / 1 tableta - tramadol

NOAX 50 mg orodisperzibilne tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

noax 50 mg orodisperzibilne tablete

angelini pharma Ősterreich gmbh - tramadol - orodisperzibilna tableta - tramadol 43,92 mg / 1 tableta - tramadol

Lymphoseek Evropska unija - slovenščina - EMA (European Medicines Agency)

lymphoseek

navidea biopharmaceuticals europe ltd. - tilmanocept - radionuklidno slikanje - tumor odkrivanje, diagnostiko, radiofarmacevtskih izdelkih - to zdravilo je samo za diagnostično uporabo. radioaktivno označiti lymphoseek je primerna za slikanje in intraoperative odkrivanje sentinel bezgavk odvajanje primarnega tumorja pri odraslih bolnikih z rakom dojke, melanom, ali lokalizirana skvamoznih celic karcinom ustne votline. zunanje imaging in intraoperative ovrednotenje se lahko izvede z uporabo gama odkrivanje naprave.

Deferasirox Mylan Evropska unija - slovenščina - EMA (European Medicines Agency)

deferasirox mylan

mylan pharmaceuticals limited - deferasiroks - iron overload; beta-thalassemia - kelator železa - deferasirox mylan je označena forthe zdravljenje kronične železa preobremenitve zaradi pogoste transfuzije krvi (≥7 ml/kg/mesec pakirani rdečih krvničk) pri bolnikih z beta talasemija major, starih 6 let in olderthe zdravljenje kronične železa preobremenitve zaradi transfuzije krvi, če deferoxamine zdravljenje je kontraindicirano ali neustrezni v naslednjih bolnik skupine:v pediatričnih bolnikih z beta talasemija major preobremenitve z železom zaradi pogoste transfuzije krvi (≥7 ml/kg/mesec pakirani rdečih krvnih celic), starih od 2 do 5 let,pri odraslih in pediatričnih bolnikih z beta talasemija major preobremenitve z železom zaradi redke transfuzije krvi (.

Trudexa Evropska unija - slovenščina - EMA (European Medicines Agency)

trudexa

abbott laboratories ltd. - adalimumab - spondylitis, ankylosing; arthritis, rheumatoid; arthritis, psoriatic; crohn disease - imunosupresivi - revmatoidni arthritistrudexa v kombinaciji z metotreksatom, je indicirano za:zdravljenje zmerno do hudo aktivnega revmatoidnega artritisa pri odraslih bolnikih, kadar je odziv na bolezni-spreminjanje anti-revmatičnih drog, vključno z metotreksatom je nezadostna. zdravljenje hude, aktivne in postopno revmatoidni artritis pri odraslih, ki še niso bila obdelana z metotreksatom. trudexa lahko podana kot monotherapy v primeru nestrpnost do metotreksatom ali ko nadaljnje zdravljenje z metotreksatom ni primerno. trudexa je dokazano, da zmanjša stopnjo napredovanja skupno škodo, merjeno z x-ray in izboljšati telesno funkcijo, če bi imeli v kombinaciji z metotreksatom. psoriatični arthritistrudexa je primerna za zdravljenje aktivnega in postopno psoriatičnega artritisa pri odraslih, ko je odgovor na prejšnje bolezni spreminjajo anti-revmatičnih zdravljenja z zdravili je bila neustrezna. ankilozirajoči spondylitistrudexa je indiciran za zdravljenje odraslih s hudo aktivno ankilozirajoči spondilitis, ki so imeli nezadosten odgovor na konvencionalne terapije. crohnova diseasetrudexa je indiciran za zdravljenje hude, aktivne crohnovo boleznijo, pri bolnikih, ki se niso odzvali, kljub temu polno in ustrezni tečaj zdravljenja s kortikosteroidi in/ali immunosuppressant; ali, ki ne prenašajo ali imajo medicinske kontraindikacije za takšne terapije. za indukcijsko zdravljenje, trudexa je treba v kombinaciji z cortiocosteroids. trudexa lahko podana kot monotherapy v primeru nestrpnost do kortikosteroidi ali ko je nadaljevalo zdravljenje s kortikosteroidi ni primerno (glej poglavje 4.